Enzyme cascade reaction system for nucleic acid and protein molecule detection and application

Through the synergistic effect of BER endonuclease and Argonaute endonuclease in the enzyme cascade reaction system, the fluorescence signal is generated by cleavage of single-stranded DNA probes, and rapid detection of nucleic acid and protein biomarkers without pre-amplification is achieved. The problem of complex and long-term detection methods in the prior art is achieved, and efficient and sensitive instant detection is achieved.

CN119082268AActive Publication Date: 2024-12-06ZHEJIANG UNIV

Patent Information

Application Number
CN202411086857.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-12-06
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

Existing methods for nucleic acid and protein molecule detection are complex, long-term and dependent on specific instruments, making it difficult to achieve fast, accurate and user-friendly instant detection, especially in resource-constrained environments.

Method used

Using an enzyme cascade reaction system, combining the coenzyme activities of BER endonucleases (such as APE1) and Argonaute endonucleases (such as pfAgo), real-time detection within 45 minutes without pre-amplification of nucleic acids and protein biomarkers. Fluorescence signals were generated by cleavage of a designed single-stranded DNA probe and enzyme cascade reaction system for detection.

Benefits of technology

It realizes fast, low-cost, and high-sensitivity nucleic acid and protein biomarker detection, and can obtain results within 45 minutes without complex equipment and steps. It is suitable for on-site applications and improves diagnostic accuracy and therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082268A_ABST
    Figure CN119082268A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological detection, and provides an enzyme cascade reaction system for nucleic acid and protein molecule detection, which comprises a BER endonuclease and an Argonaute endonuclease, wherein the BER endonuclease is selected from one or more of APE1, FEN1, Fpg, UDG and T7 endonuclease, and the Argonaute endonuclease is selected from one or more of pfAgo, CpAgo, CbAgo, TtAgo, RasAgo, MjAgo and NgAgo. The invention further provides a nucleic acid and protein molecule detection method adopting the system and application of the system in preparation of products for detecting sample target nucleic acid and target protein molecules. According to the present invention, by using the synergistic enzyme activity of APE1 and PfAgo in the enzyme cascade reaction system, the real-time detection of the nucleic acid and the protein biomarker without pre-amplification can be achieved within 45 min;
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection technology, and in particular to an enzyme cascade reaction system for nucleic acid and protein molecule detection and its application. Background Art

[0002] Biomarkers (including nucleic acids and proteins) can provide comprehensive diagnostic information and play an important role in improving the clinical management of complex diseases, including risk assessment, early detection, treatment or monitoring. Gold standard methods such as polymerase chain reaction (PCR) and reverse transcription polymerase chain reaction (RT-PCR) are used to detect nucleic acid markers, and immunological methods are widely used to detect protein markers. However, these methods are usually complicated to operate, time-consuming (4 to 6 hours), and dependent on specific instruments, resulting in a growing demand for faster, more accurate, and user-friendly diagnostic tools.

[0003] Simple and portable point-of-care testing (POCT) that can be performed in resource-limited locations or when generally needed is critical in disease control, food safety, and environmental monitoring. Programmable nucleases with sequence-specific catalytic properties, particularly clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated protein (Cas) systems, have attracted much attention for their potential in molecular diagnostics. Certain Cas proteins exhibit accessory cleavage activity on nonspecific targets, a unique property that has enabled the development of CRISPR-based point-of-care (POC) platforms, such as SHERLOCK and DETECTR, that have high specificity and sensitivity. However, challenges facing the CRISPR / Cas system, including its reliance on the protospacer adjacent motif (PAM) and the increased cost and instability associated with the guide RNA, may hinder its widespread use in diagnostics.

[0004] Argonautes are similar to Cas proteins and are also programmable nucleases. Eukaryotic Argonautes (eAgos) play a key role in the RNA interference (RNAi) pathway and participate in various cellular processes such as transcriptional and post-transcriptional gene silencing, host defense mechanisms, etc. Prokaryotic Argonautes (pAgos) are widely used in molecular detection. Most pAgos use a short DNA guide (gDNA) and can cut the complementary strand between the 10th and 11th bases from the 5' end of the guide without a protospacer adjacent motif (PAM). However, mesophilic pAgos (CbAgo, CpAgo, and IbAgo) are reported to lack the ability to digest dsDNA targets with high GC content due to their inability to unwind dsDNA, which may limit their application in nucleic acid detection. In contrast, the recent research progress of thermophilic pAgo (PfAgo, TtAgo) has made it occupy an important position in nucleic acid detection and become the focus of biosensor research. Taking advantage of their high temperature resistance, thermophilic pAgo overcomes the challenge of opening double-stranded DNA (dsDNA) duplexes. However, their current applications are limited to nucleic acid detection after amplification. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide an enzyme cascade reaction system and application for nucleic acid and protein molecule detection. By utilizing the synergistic enzyme activity of APE1 and PfAgo in the enzyme cascade reaction system, instant detection of nucleic acid and protein biomarkers without pre-amplification can be achieved within 45 minutes.

[0006] The present invention adopts the following technical solutions to solve the above technical problems:

[0007] The invention provides an enzyme cascade reaction system for nucleic acid and protein molecule detection, comprising BER endonuclease (base excision repair endonuclease) and Argonaute endonuclease.

[0008] As one of the preferred embodiments of the present invention, the BER endonuclease is one or more of APE1, FEN1, Fpg, UDG, and T7 endonuclease, and more preferably APE1.

[0009] As one of the preferred embodiments of the present invention, the Argonaute endonuclease is one or more of pfAgo, CpAgo, CbAgo, TtAgo, RasAgo, MjAgo, and NgAgo, more preferably pfAgo.

[0010] The present invention also provides a method for detecting a target DNA or RNA nucleic acid molecule in a sample, using the above enzyme cascade reaction system, comprising the following steps:

[0011] (1) The sample is first contacted with the following substances: BER endonuclease and single-stranded DNA probe P1;

[0012] (2) contacting and mixing Argonaute endonuclease, two exogenous single-stranded DNA probes P2 and P3 with the reaction solution of step (1);

[0013] (3) The target DNA or RNA of the sample is detected by measuring the detection signal generated by the enzyme cascade reaction system cleaving the three single-stranded DNA probes.

[0014] As one of the preferred embodiments of the present invention, the sample is a DNA or RNA molecule from serum, plasma, tissue, oropharyngeal swab, urine or feces.

[0015] As one of the preferred embodiments of the present invention, the single-stranded DNA probes P1, P2, and P3 are probes designed for sample target DNA or RNA molecules.

[0016] As one of the preferred embodiments of the present invention, the single-stranded DNA probe P1 is AP-modified.

[0017] As one of the preferred embodiments of the present invention, the BER endonuclease specifically cuts the AP site of the single-stranded DNA probe P1 and generates ssDNA modified with a 5'-end phosphate group, i.e., gDNA1, at the cutting site; at the same time, in the process of the BER endonuclease specifically cutting the single-stranded DNA probe P1, a first fluorescent signal to be detected is generated.

[0018] As one of the preferred embodiments of the present invention, the Argonaute endonuclease uses gDNA1 as a guide DNA to specifically identify the single-stranded DNA probe P2, and cuts the single-stranded DNA probe P2 at the 10th to 11th position away from the 5' end of the gDNA1 to generate gDNA2 and a second fluorescent signal to be detected.

[0019] As one of the preferred embodiments of the present invention, the Argonaute endonuclease again utilizes gDNA2 to specifically recognize the single-stranded DNA probe P3, cuts the single-stranded DNA probe P3 at the 10th to 11th position away from the 5' end of the gDNA2, and generates a third fluorescent signal to be detected.

[0020] As one of the preferred methods of the present invention, when used for miR-21 detection:

[0021] The base sequences of the single-stranded DNA probes P1, P2, and P3 are shown in SEQ ID NOs. 1 to 3, respectively;

[0022] When the BER endonuclease cuts the probe P1, the gDNA1 produced has base sequences as shown in SEQ ID NO.4;

[0023] The Argonaute endonuclease cleaves the probe P2 to generate gDNA2, the base sequences of which are shown in SEQ ID NO.5.

[0024] In summary, the nucleic acid molecule detection principle of the present invention is as follows Figure 1 As shown, it can be summarized into the following processes:

[0025] (1) Probe P1 specifically binds to the target DNA or RNA to form a double-stranded structure, and the BER endonuclease (APE1 as an example) specifically cleaves the AP site of P1 to produce gDNA1;

[0026] (2) gDNA1 in reaction (1) further acts as a guide DNA to specifically recognize probe P2, guiding Argonaute endonuclease (taking pfAgo as an example) to specifically cut probe P2;

[0027] (3) the newly generated gDNA2 in reaction (2) acts as a guide DNA, further triggering the cleavage of probe P3 by Argonaute endonuclease (i.e., pfAgo);

[0028] (4) Achieve triple signal release and be detected.

[0029] The nucleic acid detection method can detect pathogenic microorganisms, gene mutations or disease-related DNA or RNA nucleic acid molecule markers.

[0030] The present invention also provides a method for detecting protein molecules in a sample, using the above enzyme cascade reaction system, comprising the following steps:

[0031] (1) The sample contains BER endonuclease protein molecules; first, the sample is contacted with the following substances: DNA probes S1, S2, and S3;

[0032] (2) contacting and mixing the Argonaute endonuclease and DNA probe S4 with the reaction solution of step (1);

[0033] (3) Measure the detection signal generated by the enzyme cascade reaction system cutting the DNA probes S2, S3, and S4, thereby detecting the protein molecules in the sample.

[0034] As one of the preferred embodiments of the present invention, the sample is a protein molecule from serum, plasma, tissue, oropharyngeal swab, urine or feces.

[0035] As one of the preferred embodiments of the present invention, the DNA probes S1, S2, S3, and S4 are probes designed for sample target protein molecules.

[0036] As one of the preferred embodiments of the present invention, the DNA probes S1, S2, and S3 are all Flap structure probes.

[0037] As one of the preferred embodiments of the present invention, the BER endonuclease specifically cuts the DNA probe S2 and generates ssDNA with a 5'-terminal phosphate group modification, namely gDNA3; when the DNA probe S2 is cut, a first fluorescent signal to be detected is generated.

[0038] As one of the preferred embodiments of the present invention, the Argonaute endonuclease uses gDNA3 as a guide DNA to specifically recognize DNA probe S3, cuts DNA probe S3 at positions 10 to 11 from the 5' end of gDNA3, generates gDNA4, and generates a second fluorescent signal to be detected.

[0039] As one of the preferred embodiments of the present invention, the Argonaute endonuclease again utilizes gDNA4 to specifically recognize the DNA probe S4, cuts the DNA probe S4 at the 10th to 11th position away from the 5' end of gDNA4, and generates a third fluorescent signal to be detected.

[0040] As one of the preferred methods of the present invention, when specifically used for FEN1 protein molecule detection:

[0041] The base sequences of the DNA probes S1, S2, S3, and S4 are shown in SEQ ID NOs. 6 to 9, respectively;

[0042] The BER endonuclease cleaves the probe S2 to generate gDNA3, whose base sequences are shown in SEQ ID NO.10;

[0043] The Argonaute endonuclease cleaves the probe S3 to generate gDNA4, the base sequences of which are shown in SEQ ID NO.11.

[0044] Detection principle Figure 2 As shown, it includes the following processes:

[0045] (1) The BER endonuclease protein molecule (taking FEN1 as an example) specifically cleaves the probe S2 (FlapDNA probe) and produces gDNA3;

[0046] (2) gDNA3 in reaction (1) further acts as a guide DNA to specifically recognize probe S3, and guide Argonaute endonuclease (taking pfAgo as an example) to specifically cut probe S3, thereby generating gDNA4;

[0047] (3) the newly generated gDNA4 in reaction (2) serves as a guide DNA, further triggering the cleavage of probe S4 by Argonaute endonuclease (i.e., pfAgo);

[0048] (4) Realize triple signal release and detection.

[0049] In addition, the present invention can also be used for the detection of APE1 protein molecules. In this case, the aforementioned probes P2 and P3 can also be used. The detection principle is as follows: Figure 2 shown.

[0050] The protein molecule detection method of the present invention can detect pathogenic microorganisms, gene mutations or disease-related protein molecule markers.

[0051] At the same time, the present invention also provides an application of the above enzyme cascade reaction system in the preparation of detection sample target nucleic acid and target protein molecule reagent products.

[0052] In the present invention, an enzyme cascade reaction system named NAPTUNE (Nucleic acid and Protein Biomarkers Testing via Ultra-sensitive Nucleases Escalation) was developed. Through the use of tandem endonucleases, nucleic acid and protein biomarker detection without pre-amplification within 45 minutes was achieved. The designed NAPTUNE of the present invention uses a purinic / apyrimidinic BER endonuclease (e.g., APE1) and an Argonaute endonuclease (e.g., pfAgo) for synergistic action. First, APE1 itself can establish a positive feedback loop for target nucleic acid detection, with high specificity and exponential signal amplification characteristics. At the same time, the continuous cleavage product with a 5-terminal phosphate end produced by APE1 cleavage can serve as a guide for gDNA, activating the cis-cleavage system on the secondary and tertiary probes mediated by PfAgo, thereby converting the ability of APE1 to recognize targets into an "APE1-Argonaut" in situ cascade amplification fluorescence signal mode. This groundbreaking approach exploits the synergistic enzymatic activities of BER endonucleases and Argonaute endonucleases, paving the way for an enhanced and efficient signal amplification process to achieve highly sensitive, amplification-free, rapid, highly specific, single-tube, and on-site detection of nucleic acids, especially non-coding RNA (ncRNA).

[0053] In addition, the present invention validated NAPTUNE using RNA samples extracted from patient tissues. Using directly synthesized probes, we utilized the in situ cascade strategy that is integral to the NAPTUNE method and deployed it to detect protein biomarkers (e.g., FEN1), further demonstrating the programmability of the platform. The use of NAPTUNE is expected to improve the ability to analyze nucleic acid and protein biomarkers on-site, even for minimally trained individuals, thereby significantly improving diagnostic accuracy and therapeutic efficacy in clinical applications.

[0054] The advantages of the present invention compared to the prior art are:

[0055] (1) Rapidity: When the test conditions are ready, the present invention only takes 30 to 60 minutes from obtaining the sample to obtaining the test results. In most cases, real-time detection of nucleic acid and protein biomarkers that do not require pre-amplification can be achieved within 45 minutes.

[0056] (2) Low cost: The system and method of the present invention do not involve special materials or enzymes, and the materials and reagents involved are relatively small, so micro-quantity testing and analysis can be performed;

[0057] (3) High efficiency: The present invention has extremely high sensitivity and can detect DNA or RNA at a concentration of 1aM and protein molecule markers at 1U / L;

[0058] (4) Simple: There are no special complicated steps, no need for complex equipment and laboratories, and on-site testing can be achieved by simply adding samples. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 This is a schematic diagram of the principle of nucleic acid molecule detection based on the enzyme cascade reaction system of the present invention;

[0060] Figure 2 This is a schematic diagram of the protein molecule detection principle based on the enzyme cascade reaction system of the present invention;

[0061] Figure 3 It is a real-time fluorescence signal diagram of the feasibility analysis of NAPTURE detection of miR-21 in Experimental Example 1;

[0062] Figure 4 is a fluorescence intensity graph of the sensitivity analysis of miR-21 detected by NAPTURE in Experimental Example 2;

[0063] Figure 5 is the fluorescence intensity graph of miR-21 in clinical samples detected by NAPTURE and qPCR in Experimental Example 3;

[0064] Figure 6This is a PAGE detection diagram of the feasibility analysis of NAPTURE detection of FEN1 in Experimental Example 4;

[0065] Figure 7 is a linear relationship diagram between the fluorescence intensity and FEN1 concentration of the sensitivity analysis of FEN1 detected by NAPTURE in Experimental Example 5;

[0066] Figure 8 This is a graph of the FEN1 fluorescence intensity of simulated clinical samples detected by NAPTURE in Experimental Example 6 (in the figure, “***” indicates P<0.001). DETAILED DESCRIPTION

[0067] The following is a detailed description of an embodiment of the present invention. This embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation method and a specific operation process are given, but the protection scope of the present invention is not limited to the following embodiment.

[0068] The invention provides a NAPTURE system for nucleic acid and protein molecule detection and a nucleic acid and protein molecule detection method based on the system.

[0069] The NAPTURE system includes BER endonuclease and Argonaute endonuclease. The BER endonuclease is one or more of APE1, FEN1, Fpg, UDG, and T7 endonuclease, preferably APE1. The Argonaute endonuclease is one or more of pfAgo, CpAgo, CbAgo, TtAgo, RasAgo, MjAgo, and NgAgo, preferably pfAgo.

[0070] In the nucleic acid detection method based on the NAPTURE system, the sample is DNA or RNA molecules from serum, plasma, tissue, oropharyngeal swab, urine or feces.

[0071] In the protein molecule detection method based on the NAPTURE system, the samples are BER endonuclease protein molecules from serum, plasma, tissue, oropharyngeal swab, urine or feces, such as APE1, FEN1, etc.

[0072] At the same time, in the detection of nucleic acid molecules in the following embodiments, taking microRNA 21 (miR-21, a small molecular weight non-coding RNA) as an example, the probes P1 to P3 used have sequences as shown in SEQ ID NOs. 1 to 3, and the gDNA1 and gDNA2 sequences generated during the detection process are shown in SEQ ID NOs. 4 to 5 (see Table 1).

[0073] In the detection of protein molecules in the following examples, taking FEN1 enzyme as an example, probes S1 to S4 probes are used, and their sequences are shown in SEQ ID NOs. 6 to 9. The gDNA3 and gDNA4 sequences generated during the detection process are shown in SEQ ID NOs. 10 to 11 (see Table 1).

[0074] In addition, the reagents and experimental methods used in the following examples, unless otherwise specified, are conventional reagents or methods in the art and will not be described in detail.

[0075] Table 1 The present invention relates to probes and gDNA

[0076] name Sequence (5'-3') Serial Number Probe P1 TCAACAnCAGTCTGATAAGCTAT SEQ ID NO.1 Probe P2 AAACATAGCTTATCAGACTGCCCAGC SEQ ID NO.2 Probe P3 ATATCCGGCTGGACAGTCTGATATGA SEQ ID NO.3 gDNA1 CAGTCTGATAAGCTAT SEQ ID NO.4 gDNA2 TATCAGACTGCCCAGC SEQ ID NO.5 Probe S1 GTCGAGAATCCTGCTGGG SEQ ID NO.6 Probe S2 ATTTCGGCAGAGACCTAATATAAGCAAAAC SEQ ID NO.7 Probe S3 GTTTTGCTTATATTAGGTCTCCCAGCAGGATTCTCGAC SEQ ID NO.8 Probe S4 ATATCCGGCTGGGAGACCTAATATGA SEQ ID NO.9 gDNA3 AGACCTAATATAAGCAAAAC SEQ ID NO.10 gDNA4 TATTAGGTCTCCCAGCAGGATTCTCGAC SEQ ID NO.11

[0077] Note: n is the AP site.

[0078] Example 1: NAPTURE detection of miR-21 molecules:

[0079] (1) For a 20-uL reaction system, 2 μL of synthetic miR-21 (the sequence of miR-21 is “UAGCUUAUCAGACUGAUGUUGA”) or extracted RNA sample was reacted with 2 μL of 1 μM probe P1 at 90°C for 1 min, and then cooled to room temperature to obtain a double-stranded structure.

[0080] (2) The formed double-stranded structure was mixed with 6 μL APE1 reaction solution (50 mM Tris / HCl pH 7.4, 100 mM KCl, 5 mM MgCl2, 2 mM ATP, 0.05 mg / mL BSA, 100 mU / mL APE1) and reacted at 42°C for 20 min.

[0081] (3) After the APE1 reaction was completed, 10 μL of pfAgo reaction solution (250 nM pfAgo protease, 200 nM probe P2, 200 nM probe P3, 20 mM HEPES pH 7.5, 250 mM NaCl, 0.5 mM MnCl2) was added to the mixture and reacted at 95°C for 25 minutes.

[0082] (4) The fluorescence intensity of the final reaction solution was recorded using an ELISA instrument, and the real-time fluorescence signal was detected using a qPCR device (Bio-Rad, CFXconnect Real-Time System).

[0083] Example 2: NAPTURE detection of FEN1 protein molecules:

[0084] (1) Take 2 μL of each of the 2 μM probes S1, S2, and S3 and add 38 μL of TE buffer, denature at 90°C for 1 min, and then cool to room temperature to obtain a composite structure.

[0085] (2) Add 2 μL of the purchased FEN1 enzyme or the obtained simulated sample solution to 1 μL of the aforementioned composite structure probe, then add 7 μL of H2O and 1 μL of 10x ThermoPol reaction buffer, and react at 65°C for 20 min.

[0086] (3) After the reaction, 10 μL of pfAgo reaction solution (250 nM pfAgo protease, 250 nM probe S4, 20 mM HEPES pH 7.5, 250 mM NaCl, 0.5 mM MnCl2) was added to the mixture and reacted at 95°C for 25 min.

[0087] (4) The final product bands were detected by non-denaturing polyacrylamide gel electrophoresis (PAGE) experiment, and the fluorescence intensity of the final reaction solution was read by an ELISA reader.

[0088] Experimental Example 1: Feasibility analysis of the NAPTURE method for detecting miR-21 of the present invention:

[0089] In order to analyze the feasibility of NAPTURE to detect miR-21, probes P1 to P3 labeled with FAM-BHQ1 were used to verify the signal amplification achieved by APE1 and pfAgo reaction. Eight groups of experiments were designed for verification.

[0090] The results are as follows Figure 3 As shown: when Target (i.e. miR-21) and P1, APE1, pfAgo, P2, and P3 are all present, the final fluorescence signal is the strongest, and the results suggest "tertiary signal amplification achieved by APE1 reaction and pfAgo secondary cutting"; when probe P3 is missing, the fluorescence signal weakens, and the results suggest "in the absence of probe P3, pfAgo cannot perform secondary cutting, but there is secondary signal amplification achieved by APE1 reaction and pfAgo primary cutting"; when probe P2 or pfAgo is missing, the fluorescence signal is further weakened, and the results suggest "even if probe P3 is present but probe P2 or pfAgo is missing, pfAgo reaction cannot be performed, and there is only primary signal amplification achieved by APE reaction"; when Target or APE1 is missing in the system, the fluorescence signal is the same as the group with only P1, P2, and P3 probes, with almost no fluorescence signal, and the results suggest "in the absence of Target or APE1, APE1 reaction cannot occur, that is, no signal is generated." The results showed that NAPTURE achieved tertiary signal amplification using APE1 and pfAgo reactions and could be used to detect miR-21.

[0091] Experimental Example 2: Sensitivity analysis of the NAPTURE method for detecting miR-21 of the present invention:

[0092] In order to determine the sensitivity of NAPTURE for miR-21 detection, the synthesized miR-21 was diluted to 0-10 pM, and the NAPTURE reaction was performed using probes P1-P3 labeled with FAM-BHQ1. After the reaction, the FAM fluorescence signal intensity was detected using an ELISA reader.

[0093] The results are as follows Figure 4 The results showed that the sensitivity of detecting miR-21 was as low as 1aM. The results showed that NAPTURE can be used for sensitive detection of miR-21.

[0094] Experimental Example 3: Clinical sample verification of the NAPTURE method for detecting miR-21 of the present invention:

[0095] In order to explore the feasibility of NAPTURE to detect miR-21 in actual samples, RNA was extracted from tissue samples of 30 children with neuroblastoma, and the miR-21 expression level of the 30 sample RNAs was detected by real-time quantitative reverse transcription PCR (qPCR) and NAPTURE, respectively.

[0096] The results are as follows Figure 5 The results showed that the NAPTURE test results were well consistent with the qPCR results, reaching 95.3% positive prediction and 91.0% negative prediction. The results showed that the NAPTURE of the present invention has the ability to accurately detect miR-21 in clinical samples.

[0097] Experimental Example 4: Feasibility analysis of the NAPTURE method for detecting FEN1 of the present invention:

[0098] In order to analyze the feasibility of NAPTURE to detect FEN1, we designed 6 sets of experiments for verification using probe S2 labeled with Cy3, probe S3 labeled with Cy5, and probe S4 labeled with FAM.

[0099] The results are as follows Figure 6As shown: The first group (Flap group in the figure) shows the complex structure formed by probes S1, S2 and S3. The second group (Flap+FEN1 group in the figure) shows that when the FEN1 enzyme is present, the S2 probe is cut into short fragments. The results suggest that the presence of the FEN1 enzyme can mediate the cleavage of the S2 probe. After further adding pfAgo, compared with the third group (Flap+pfAgo group in the figure), the fourth group (Flap+FEN1+pfAgo group in the figure) shows that when the FEN1 enzyme is present, the S2 probe is cut into short fragments. When FEN1 enzyme was added, S3 was further cut into short fragments, indicating that the presence of FEN1 enzyme can mediate the cleavage of probe S3 by pfAgo; after further adding probe S4, compared with the fifth group (Flap+pfAgo+S4 group in the figure), the sixth group (Flap+FEN1+pfAgo+S4 group in the figure) showed that when probe S3 was present, S4 was further cut into short fragments, indicating that the presence of FEN1 enzyme can mediate the secondary cleavage of probe S4 by pfAgo. The results show that NAPTURE can achieve triple probe cleavage using FEN1 and pfAgo reactions and can be used to detect FEN1 enzymes.

[0100] Experimental Example 5: Sensitivity analysis of the NAPTURE method for detecting FEN1 of the present invention:

[0101] In order to determine the sensitivity of NAPTURE for FEN1 detection, the FEN1 enzyme was diluted to 0-300 mU / mL, and the NAPTURE reaction was performed using probes S2-S4 labeled with FAM-BHQ1. After the NAPTURE reaction, the FAM fluorescence signal intensity was detected using a microplate reader.

[0102] The results are as follows Figure 7 The test results showed that there was a linear relationship between the fluorescence signal intensity and the FEN1 concentration, and the sensitivity of detecting FEN1 was as low as 1mU / mL. The results showed that NAPTURE can be used for sensitive detection of FEN1.

[0103] Experimental Example 6: Simulated clinical sample verification of the NAPTURE method for detecting FEN1 of the present invention:

[0104] To explore the feasibility of NAPTURE for detecting FEN1 enzyme in biological samples, NAPTURE was used to detect FEN1 levels in simulated clinical samples with FEN1 added to serum.

[0105] The results are as follows Figure 8 The results showed that the level of FEN1 in the Minic samples was significantly increased compared with the control group (NC). The results showed that NAPTURE has the ability to accurately detect FEN1 in samples.

[0106] In summary, the novel enzyme cascade reaction system NAPTURE provided by the present invention can be used for nucleic acid and protein molecule detection, and has the characteristics of ultrasensitivity, fast reaction, low cost and on-site detection.

[0107] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An enzyme cascade reaction system for nucleic acid and protein molecule detection, characterized in that: Includes BER endonuclease and Argonaute endonuclease.

2. The enzyme cascade reaction system for nucleic acid and protein molecule detection according to claim 1, characterized in that: The BER endonuclease is one or more of APE1, FEN1, Fpg, UDG, and T7 endonuclease.

3. The enzyme cascade reaction system for nucleic acid and protein molecule detection according to claim 1, characterized in that: The Argonaute endonuclease is one or more of pfAgo, CpAgo, CbAgo, TtAgo, RasAgo, MjAgo, and NgAgo.

4. A method for detecting a target DNA or RNA nucleic acid molecule in a sample, characterized in that: The enzyme cascade reaction system according to any one of claims 1 to 3 comprises the following steps: (1) The sample is first contacted with the following substances: BER endonuclease and single-stranded DNA probe P1; (2) contacting and mixing Argonaute endonuclease, two exogenous single-stranded DNA probes P2 and P3 with the reaction solution of step (1); (3) The target DNA or RNA of the sample is detected by measuring the detection signal generated by the enzyme cascade reaction system cleaving the three single-stranded DNA probes.

5. The method for detecting a target DNA or RNA nucleic acid molecule in a sample according to claim 4, characterized in that: The sample is DNA or RNA molecules from serum, plasma, tissue, oropharyngeal swab, urine or feces.

6. The method for detecting a target DNA or RNA nucleic acid molecule in a sample according to claim 4, characterized in that: The single-stranded DNA probes P1, P2, and P3 are probes designed for sample target DNA or RNA molecules.

7. The method for detecting a target DNA or RNA nucleic acid molecule in a sample according to claim 4, characterized in that: The single-stranded DNA probe P1 is AP-modified.

8. The method for detecting a target DNA or RNA nucleic acid molecule in a sample according to claim 4, characterized in that: The BER endonuclease specifically cuts the AP site of the single-stranded DNA probe P1 and generates ssDNA with a 5'-terminal phosphate group modification, namely gDNA1, at the cutting site; meanwhile, in the process of the BER endonuclease specifically cutting the single-stranded DNA probe P1, a first fluorescent signal to be detected is generated.

9. The method for detecting a target DNA or RNA nucleic acid molecule in a sample according to claim 8, characterized in that: The Argonaute endonuclease uses gDNA1 as a guide DNA to specifically recognize the single-stranded DNA probe P2, and cuts the single-stranded DNA probe P2 at the 10th to 11th position away from the 5' end of the gDNA1 to generate gDNA2 and a second fluorescent signal to be detected.

10. The method for detecting a target DNA or RNA nucleic acid molecule in a sample according to claim 9, characterized in that: The Argonaute endonuclease again utilizes gDNA2 to specifically recognize the single-stranded DNA probe P3, and cuts the single-stranded DNA probe P3 at the 10th to 11th position away from the 5' end of the gDNA2, and generates a third fluorescent signal to be detected.

11. The method for detecting a target DNA or RNA nucleic acid molecule in a sample according to any one of claims 4 to 10, characterized in that: When used for miR-21 detection: The base sequences of the single-stranded DNA probes P1, P2, and P3 are shown in SEQ ID NOs. 1 to 3, respectively; When the BER endonuclease cuts the probe P1, the gDNA1 produced has base sequences as shown in SEQ ID NO.4; The Argonaute endonuclease cleaves the probe P2 to generate gDNA2, the base sequences of which are shown in SEQ ID NO.

5.

12. A method for detecting protein molecules in a sample, characterized in that: The enzyme cascade reaction system according to any one of claims 1 to 3 comprises the following steps: (1) The sample contains BER endonuclease protein molecules; first, the sample is contacted with the following substances: DNA probes S1, S2, and S3; (2) contacting and mixing the Argonaute endonuclease and DNA probe S4 with the reaction solution of step (1); (3) Measure the detection signal generated by the enzyme cascade reaction system cutting the DNA probes S2, S3, and S4, thereby detecting the protein molecules in the sample.

13. The method for detecting protein molecules in a sample according to claim 12, characterized in that: The sample is a protein molecule from serum, plasma, tissue, oropharyngeal swab, urine or feces.

14. The method for detecting protein molecules in a sample according to claim 12, characterized in that: The DNA probes S1, S2, S3, and S4 are probes designed for sample target protein molecules.

15. The method for detecting protein molecules in a sample according to claim 12, characterized in that: The DNA probes S1, S2 and S3 are all Flap structure probes.

16. The method for detecting protein molecules in a sample according to claim 13, characterized in that: The BER endonuclease specifically cuts the DNA probe S2 and generates ssDNA with a 5'-terminal phosphate group modification, namely gDNA3; when the DNA probe S2 is cut, a first fluorescent signal to be detected is generated.

17. The method for detecting protein molecules in a sample according to claim 16, characterized in that: The Argonaute endonuclease uses gDNA3 as a guide DNA to specifically recognize DNA probe S3, cuts DNA probe S3 at the 10th to 11th position away from the 5' end of gDNA3, generates gDNA4, and generates a second fluorescent signal to be detected.

18. The method for detecting protein molecules in a sample according to claim 17, characterized in that: The Argonaute endonuclease again utilizes gDNA4 to specifically recognize the DNA probe S4, cuts the DNA probe S4 at the 10th to 11th position away from the 5' end of gDNA4, and generates a third fluorescent signal to be detected.

19. The method for detecting protein molecules in a sample according to any one of claims 12 to 18, characterized in that: When used for FEN1 protein molecular detection: The base sequences of the DNA probes S1, S2, S3, and S4 are shown in SEQ ID NOs. 6 to 9, respectively; The BER endonuclease cleaves the probe S2 to generate gDNA3, whose base sequences are shown in SEQ ID NO.10; The Argonaute endonuclease cleaves the probe S3 to generate gDNA4, the base sequences of which are shown in SEQ ID NO.

11.

20. Use of the enzyme cascade reaction system according to any one of claims 1 to 3 in preparing a reagent product for detecting a sample target nucleic acid and a target protein molecule.

Citation Information

Patent Citations

  • Gene editing technique taking Argonaute nuclease as core

    CN105483118A

  • CRISPR / SpRY (clustered regularly interspaced short palindromic repeats / SpRY) detection system and gene mutation detection method thereof

    CN117467750A

  • Nucleic acid analysis

    WO2024084439A2

  • Nucleic acid enrichment and detection

    WO2024084440A1

Cited By

  • Integrated micro-fluidic chip for joint detection of nucleic acid and protein and detection method

    CN121819967A